Increased Serum IgG Antibody, Avidity, and Surrogate Virus Neutralization Response after a Third Dose for the BNT162b2 mRNA Vaccine to SARS-CoV-2

J Appl Lab Med. 2022 Jun 30;7(4):995-997. doi: 10.1093/jalm/jfac018.
No abstract available

MeSH terms

  • BNT162 Vaccine
  • COVID-19* / prevention & control
  • Humans
  • Immunoglobulin G*
  • SARS-CoV-2 / genetics
  • Vaccines, Synthetic
  • mRNA Vaccines

Substances

  • Immunoglobulin G
  • Vaccines, Synthetic
  • mRNA Vaccines
  • BNT162 Vaccine